CD8A and pancreatic ductal adenocarcinoma: In patients with pancreatic ductal adenocarcinoma, mFOLFIRINOX chemotherapy increases CD226 expression on peripheral blood CD8 + T cells, which is positively correlated with antigen-specific CD8 + T-cell responses following TIGIT or PD-1 blockade.